富祥藥業(300497.SZ):子公司取得年產1萬噸VC項目環評批覆
格隆匯3月24日丨富祥藥業(300497.SZ)公佈,近日,公司全資子公司景德鎮富祥生命科技有限公司(簡稱“富祥科技”)收到景德鎮市生態環境局下發的《關於景德鎮富祥生命科技有限公司富祥生物醫藥項目(二期第一階段)環境影響報吿書的批覆》(景環環評字[2022]35號)。
該批覆同意富祥科技在景德鎮陶瓷工業園區魚山醫藥產業園(景德鎮電廠南側)建設年產10,000噸VC(碳酸亞乙烯酯)項目,並且落實批覆中提出的各項環保措施和要求,嚴格執行環保“三同時”制度,確保各類污染物穩定達標排放。
截止公吿披露日,上述項目的相關工作正在加速推進中。公司將督促富祥科技按照環評批覆要求進行項目建設、管理與運營,確保項目實施和環境保護的協調和可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.